Another benefit of combinational therapies involving MDM2 inhibitors is better control over the dose-limiting toxicities associated with MDM2 inhibitor monotherapies, particularly hematological effects such as neutropenia and thrombocytopenia, as elucidated across clinical trials [36]. This evidence concerns the gene MDM2 and Decreased total neutrophil count.